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Abstract. The localization of inhibin/activin (I/A) subunits
was investigated in human normal adenohypophysial cells
and in 87 pituitary adenomas of different types, using im-
munohistochemistry. Monoclonal antibodies directed
against a, bA and bB subunits of I/A were employed. In
normal pituitary, a subunit of inhibin was detected only in
FSH-positive gonadotrophs, while bA subunit of I/A was
expressed in FSH-positive gonadotrophs, GH-cells and in a
few PRL-cells. bB subunit was found in FSH-positive go-
nadotrophs, TSH-cells and a few LH-positive gonadotrophs.
The three subunits of I/A were detected in the majority of
nonfunctioning    tumors,    while functioning adenomas
showed a significantly lower expression. This study shows
that a, bA and bB subunits of I/A are expressed by specific
adenohypophysial cell types and that they are charac-
teristically present in nonfunctioning adenomas. These re-
sults suggest that inhibins and activins may play a role in
the local regulation of pituitary hormonal secretion both in
normal adenohypophysial cells and in pituitary adenomas.
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Introduction
Inhibins and activins are regulatory factors initially
isolated from gonadal fluids on the basis of their ability
to inhibit and stimulate FSH synthesis and secretion,
acting with a long loop feedback on pituitary gonadot-
rophs [1]. Both these factors are disulphide-linked di-
meric proteins belonging to the transforming growth
factor b (TGFb superfamily, which consists of 5 families
of functionally different, but structurally related, regu-
latory molecules: TGFb and its isoforms, Müllerian in-
hibiting substance, decapentaplegic gene complex
polypeptide, cartilage-inducing factos and inhibins/ac-
tivins [2]. Inhibins are heterodimers composed of an a
subunit and one of two b subunits, bA or bB; up to now,
two forms of inhibins have been characterized: inhibin
A (aA) and inhibin B (abB) [1,3]. Activins are homo- or
heterodimers of inhibin b subunits: activin A is a bAbA
homodimer, activin B is a bBbB homodimer and activin
AB is a bAbB heterodimer [1,4,5]. Although the first
isolation of activins and inhibins dates back to 1932 [6],
molecular and functional characterization of these pro-
teins has been accomplished only in the last fifteen
years [1,7–9]. Recent investigations have shown that
inhibin/activin subunits and their mRNAs are not only
restricted to the gonads, but they are also present in a
wide variety of reproductive and non-reproductive or-
gans and tissues, including the placenta, the en-
dometrium, the adrenal glands, the bone marrow, the
kidney, the spinal cord, the brain, and specific types of
endocrine cells of the gut and pancreas  [10–14].  In
these sites, activins and inhibins can locally regulate a
number of cellular functions, exerting their activities
through autocrine/paracrine mechanisms, in addition
to the well known endocrine ones [9,15].
Inhibins and activins have also been localized in the
anterior pituitary gland, where their best known func-
tion is the local modulation of gonadotroph function. In
particular, inhibin inhibits both basal and GnRH-medi-
ated FSH synthesis and release, while activin acts in an
opposite way [1,6]. Recent studies, have provided fur-
ther details about this FSH-secretagogue activity, dem-
onstrating that inhibins are able to reduce transcription
of FSH gene and to down-regulate GnRH receptors
[16]. Further investigations, however, have pointed out
that these proteins, and particularly activin, play also a
role in the regulation of synthesis and release of growth
hormone (GH) [17] and prolactin [18]; in addition, they
are able to modulate the proliferation of GH- and PRL-
cells [18,19]. It has also been suggested that activin may
influence the phenotype of pituitary cells, intervening
in the temporary conversion from somatotrophs to go-
nadosomatotrophs during proestrus and diestrous of fe-
male rats [20]. However, most of the studies, which have
investigated the function and localization of inhibins
and activins in specific pituitary cell types, were per-
formed on animal tissues and their conclusions cannot
be easily applied to humans. Moreover, the results con-
cerning the cellular localization of activins and inhibins
are often conflicting and sometimes incomplete, with
special reference to bB subunit expression, which has
been investigated only in one study [21].
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The expression of inhibins and activins and their
subunits has also been investigated in pituitary ade-
nomas [22–24]. However, the localization of inhibin and
activin  subunits  in  the  different functional types of
pituitary adenomas has not been fully clarified.
The aim of our study was to clarify, using immunohis-
tochemical methods, whether inhibins/activin subunits
a, bA, and bB are differently expressed in the various
types of adenohypophysial cells and related tumors.
Materials and Methods
Four normal pituitary glands were obtained at autopsy
from subjects without endocrinological abnormalities
(age range: 54–84 years), while samples of 87 pituitary
adenomas were collected at transsphenoidal surgery.
Pituitary adenomas were subdivided into 47 function-
ing adenomas and 40 nonfunctioning adenomas, on the
basis of clinical symptoms and hormonal measure-
ments, and classified according to the prevalent hormo-
nal product detected immunohistochemically.
All tissue specimens were fixed in buffered formalin
(formaldehyde 4% w/v and acetate buffer 0.05 M) and
embedded in paraffin. Routinary histopathologic
evaluation was performed on 4lm-thick sections
stained with hematoxylin-eosin, Grimelius’ silver stain
and Alcian blue/periodic acid-Schiff (AB/PAS). For
imunohistochemical study, 3lm-thick sections mounted
on poly-L-lysine slides were employed. After deparaf-
finization and rehydratation through graded alcohols,
endogenous peroxidase activity was inhibited by treat-
ment with 3% hydrogen peroxide for 10 minutes. Incu-
bation with primary antibodies and antisera directed
against inhibin/activin a, bA and bB subunits and
against pituitary hormones (Table 1) was done at 48C
for 18–20 hours. Reactions were amplified employing
the avidin-biotin-peroxidase technique and developed
using 0.03% 3,39 diamino-benzidine.   Colocalization
studies were performed with double-label immu-
nostaining according to Mason and Sammons [25] and
to Lan et al. [26]. The localization of various subunits of
inhibin/activin was obtained using specific monoclonal
antibodies, as reported in Table 1. In detail, the anti-a-
subunit antibody was  a mouse  monoclonal  antibody
directed against a synthetic protein corresponding to
the 1-32 peptide  sequence of the a-subunit  of 32kd
human inhibin. The mouse monoclonal antibody di-
rected against the bA-subunit recognized a synthetic
peptide corresponding to the 82-114 protein sequence
of the bA-subunit of 32 kd human inhibin A and activin
A. The anti-bB-subunit mouse monoclonal antibody
was directed against a synthetic peptide correspond-
ing to residues 82-114 of the inhibin bB-subunit. Sec-
tions stained with antibodies directed against inhibin/
activin a and bA subunits and against FSH were pre-
treated with 0.01M citrate buffer pH 6 for 10 minutes
in a microwave overn at 750W; sections stained with
anti-bB antibody were pretreated with etylendimitrilo
tetracetic acid (EDTA) buffer pH 8 for 10 minutes in a
microwave oven at 750W; sections stained with anti-
ACTH antiserum were pretreated for 10 minutes with
0.003% subtilisin (protease type XXVII or Nagarse
preotease; P4789, Sigma, St. Louis, MO, USA).
Specificity controls consisted of absorption of anti-
bodies and antisera with 10–20 nMol of the related
antigens, substitution of the primary antibodies with
non immune serum of the same species at the same
dilution, and use of control tissues with or without the
pertinent antigen. These tests confirmed that the anti-
bodies and antisera employed were specific.
To correlate the expression of a, bA and bB subunits
of inhibin/activin in pituitary adenomas with their
clinico-pathologic features, statistical analysis was per-
formed using the Fisher’s exact test.
Results
In normal anterior pituitary we observed an intense
positivity for all inhibin/activin (I/A) subunits, a, bA
and bB, with a fraction of immunoreactive (IR) cells
variable according to the type of subunit. The positiv-
ity was granular and was located in the cytoplasm,
with a membrane reinforcement in some cells. The pos-
terior pituitary lobe did not show any positive reaction.
a subunit of inhibin was detected in about 10–20% of
adenohypophysial cells and colocalization studies
showed that a subunit of inhibin-IR cells corresponded
almost exclusively to FSH-positive gonadotrophs (Fig-
ure 1). bA subunit of I/A was more widely expressed,
being present in about 40–50% of anterior pituitary
cells. bA subunit-positive cells included about 20% of
FSH-producing gonadotrophs, very few (less than 5%)
PRL-cells and the vast majority (.90%) of GH-cells
(Figure 2). bB subunit of I/A was found in about 40%
of adenohypophysial cells and double label immunohis-
Table 1. Antibodies and antisera employed
Antibodies/
antisera* P/M Dilution Source
FSH M 1/20 Dako, Copenhagen, DK
LH M 1/100 BioGenex Laboratories,
San Ramon, CA, USA
GH M 1/200 BioGenex
PRL P undiluted Biomeda, Foster City,
CA, USA
ACTH P 1/250 Dako
ahCG M 1/5000 Dr. Ghielmi, University of
Brescia, Italy
TSH M 1/2 Biomeda
a subunit of
inhibin M 1/100 Serotec, Oxford, UK
bA subunit of
I/A M 1/100 Serotec
bB subunit of
I/A M 1/100 Serotec
M/P 5 monoclonal/polyclonal; I/A 5 inhibin/activin; * 5 all antibodies
and antisera used were directed against human peptides.
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Fig. 1. Normal autoptic pituitary gland. Double label immunostainings showing that a-subunit of inhibin (brown) is colocalized
with FSH (a), but not with GH (b). Hormones are stained in red. (Avidin-biotin-peroxidase method for brown staining and alkaline
phosphatase method for red staining, original magnification 3 1000).
Fig. 2. Normal autoptic pituitary gland. Double label immunostainings showing that bA-subunit of inhibin/activin (brown) is colo-
calized with GH (a), but not with ACTH (b). Hormones are stained in red. (Avidin-biotin-peroxidase method for brown staining and
alkaline phosphatase method for red staining, original magnification 3 1000).
tochemical stains revealed that all FSH-producing go-
nadotrophs, a  few LH-producing gonadotrophs, and
nearly all TSH-cells were bB-IR (Figure 3). ACTH-
cells were not immunoreactive for any I/A subunits.
Table 2 summarizes the immunohistochemical results
obtained in the normal pituitary gland.
The 87 pituitary adenomas were subdivided in two
groups on the basis of their functional activity: forty-
seven tumors were associated with clinical symptoms
caused by hormonal hypersecretion and were classified
as functioning, while the remaining 40, not associated
with typical endocrine syndromes, were classified as
nonfunctioning. The mean age of the patients was 46.5
years (age range: 12–71); in the group of functioning
adenomas, the mean age was 41 years, while, in the
nonfunctioning group  it was 53 years. Thirty-seven
patients were males and 46 females, for 4 patients data
about sex were not available. On the basis of
immunohistochemical results, the 47 functioning ade-
nomas were further classified as 19 GH-cells, 9 mixed
GH/PRL-cells, 12 PRL-cells and 7 ACTH-cells, while
the 40 nonfunctioning adenomas were classified into 19
gonadotroph, 9 a subunit of gonadotropin (a SU-GO)-
producing-cells, 5 null cell, 3 ACTH-cell and 4 TSH-cell
adenomas.
Tables 3 and 4 show immunohistochemical results
of pituitary adenomas, in relation to functional activ-
ity and immunophenotype. Positivity for a subunit of
inhibin was observed in 23/87 (26%) adenomas, most
of which were represented by nonfunctioning tumors
(22/40, 55%). In particular, 15/19 (79%) gonadotroph
(Figure 4), 4/9 (44%) a SU-GO-cell, 2/5 (40%) null-cell
and 1/4  (25%) TSH-cell adenomas were positive for
the a subunit of inhibin. The mean percentage of posi-
tive cells in nonfunctioning adenomas ranged from
15% to 35%. On the contrary, among 47 functioning
tumors, only one mixed GH/PRL-producing adenoma
(2%) contained rare cells (about 5%) immunoreactive
for a subunit of inhibin. The difference of the expres-
sion of a subunit of inhibin between functioning and
Fig. 3. Normal autoptic pituitary gland. Double label immunostainings showing that bB-subunit of inhibin/activin (brown) is colo-
calized with TSH (a), but not with ACTH (b). Hormones are stained in red. (Avidin-biotin-peroxidase method for brown staining and
alkaline phosphatase method for red staining, original magnification 3 1000).
Table 2. Expression of a, bA and bB subunits of
inhibin/activin in normal adenohypophysial cell types
Cell type a bA bB
FSH 1 1 1
LH – – 1
GH – 1 –
PRL – 1 –
ACTH – – –
TSH – – 1
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nonfunctioning adenomas was highly significant
(p ,  0.00001).
bA subunit of I/A was expressed by 33/86 (38%) ade-
nomas, of which 22 (66%) were nonfunctioning and 11
(33%) were functioning. In the nonfunctioning group,
12/18 (67%) gonadotroph cell, 4/9 (44%) aSU-GO-cell
(Figure 5), 2/5 (40%) null cell and 4/4 (100%) TSH-cell
adenomas were bA subunit of I/A-IR. In these tumors,
the mean percentage of bA subunit-positive cells
ranged from 45% to 77%. Among functioning tumors,
3/12 (25%) PRL-cell, 4/19 (21%) GH-cell and 4/9 (54%)
mixed GH/PRL-cell adenomas expressed bA subunit,
with a mean percentage of immunoreactive cells rang-
ing from 51% to 59%. The different expression of bA
subunit of I/A between functioning and nonfunctioning
adenomas was statistically significant (p , 0.00002).
The bB subunit was expressed in 29/71 (41%) ade-
nomas. Twenty of 35 (57%) nonfunctioning adenomas
were bB-immunoreactive, including 7/15 (47%) go-
nadotroph (Figure 6), 8/8 (100%) aSU-GO cell, 1/5
(20%)  null cell, 2/3 (67%) ACTH-cell, and  2/4  (50%)
TSH-cell adenomas. The mean percentage of bB-im-
munoreactive cells in nonfunctioning adenomas ranged
from 10% to 37%. Nine of 36 (25%) functioning ade-
nomas were positive for bB subunit of I/A, including
4/15 (27%) GH-cell, 3/8 (37%) PRL-cell and 2/6 (33%)
mixed GH/PRL cell adenomas. Also for bB-immunore-
activity, Fisher exact test revealed a statistically sig-
nificant difference between functioning and nonfunc-
tioning adenomas (p , 0.003).
At statistical analysis, a, bA and bB subunit im-
munoreactivities were not significantly related to the
sex or age of the patients.
Discussion
We have investigated the immunohistochemical ex-
pression of a, bA and bB subunits of inhibin/activin
(I/A) in normal human anterior pituitary gland and in
a series of 87 pituitary adenomas. The comprehensive
study of all three subunits composing inhibins and ac-
tivins molecules allowed us to identify the profile of
expression of the various forms of these proteins both
in normal and neoplastic pituitary cells. In fact, the
coexpression of a subunit with bA subunit of I/A was
indicative of the presence inhibin A (abA) and the co-
expression of a subunit with bB subunit was indicative
of the presence of inhibin B (abB). On the other hand,
the sole immunoreactivity for bA or bB chains was
consistent with the presence of activin A (bAbA) or
activin B (bBbB), respectively. Finally, when bA and
bB subunits were co-expressed, the presence of activin
AB (bAbB) was suggested. These data, combined with
the immunohistochemical identification of normal and
neoplastic pituitary cell types, provided a survey of the
differential distribution of activins and inhibins in dif-
Table 3. Expression of inhibin/activin subunits in nonfunctioning and functioning pituitary adenomas
a bA bB
n.(%) m.p. n.(%) m.p. n.(%) m.p.
Nonfunctioning adenomas 22/40 (55%) 23.7 22/39 (56%) 65 20/35 (57%) 17.4
Functioning adenomas 1/47 (2%) 5 11/47 (23%) 54 9/36 (25%) 52
m.p. 5 mean percentage of immunoreactive cells in positive tumors
Table 4. Expression of inhibin/activin subunits in different types of pituitary adenomas
a bA bB
n.(%) m.p. n.(%) m.p. n.(%) m.p.
Nonfunctioning adenomas
Gonadotroph 15/19 (79%) 24 12/18 (67%) 71 7/15 (47%) 12.5
aSU-GO cell 4/9 (44%) 21 4/9 (44%) 67.5 8/8 (100%) 37
null Cell 2/5 (40%) 35 2/5 (40%) 45 1/5 (20%) 10
ACTH cell 0/3 0 0/3 0 2/3 (67%) 15
TSH cell 1/4 (25%) 15 4/4 (100%) 77 2/4 (50%) 12.5
Functioning adenomas
GH cell 0/19 0 4/19 (21%) 51 4/15 (27%) 50
PRL cell 0/12 0 3/12 (25%) 59 3/8 (37%) 47
GH-PRL cell 1/9 (11%) 5 4/9 (44%) 52 2/6 (33%) 60
ACTH cell 0/7 0 0/7 0 0/7 0
m.p. 5 mean percentage of immunoreactive cells in positive tumors
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ferent adenohypophysial cell types and in various pi-
tuitary adenomas.
Our results show that, among adenohypophysial
cells, FSH-producing gonadotrophs represent the
main site of production of inhibins and activins, since
they are positive for all three subunits and therefore
express all forms of inhibins and activins. In the other
adenohypophysial cell types, I/A subunits were less
widely expressed. Nearly all GH-cells and few PRL-
cells were strongly immunoreactive only for bA
subunit, which indicates the presence of activin A. In
TSH-cells and in a fraction of LH-producing gonadot-
rophs an exclusive immunostain for bB subunit was
found, suggesting the presence of activin B. It is worth
noting that a subunit was completely lacking in cells
other than FSH-producing gonadotrophs, indicating
that gonadotrophs are the only pituitary cell type in
which inhibin is present.
The expression   of   inhibins,   activins and their
subunits in pituitary gland has been previously inves-
tigated employing different experimental techniques,
including immunohistochemistry [12,21,24,27] and
mRNA in situ hybridization [24]. In a recent work,
Sugiyama et al. [24], investigated a and bA subunit
expression in human pituitary, using both immunohis-
tochemistry and mRNA in situ hybridization. In this
study, the a subunit of inhibin was reported to be pre-
sent in all adenohypophysial cell types, while bA
subunit was only found in FSH/LH-producing go-
nadotrophs and in PRL-cells. The difference between
our results and those obtained by the authors reported
above, concerning the localization of the I/A subunits
in normal pituitary gland, may be due to the different
antibodies employed or the different species examined
[12,21,27].
The presence of I/A subunits in anterior pituitary
gland suggests that these proteins may play a role in
local regulation of pituitary function via paracrine
and/or autocrine mechanisms, in addition to their well-
known endocrine function. In particular, the expres-
sion of inhibins and activins in FSH-producing go-
nadotrophs supports the hypothesis that they may
locally modulate FSH synthesis and secretion [15], as
it has been shown by investigations on rat adenohypo-
physial cell lines [28]. A noteworthy result of our inves-
tigation is that a subunit of inhibin is localized only in
FSH-producing gonadotrophs, but not in other pitui-
tary cell types, suggesting that the expression of inhib-
ins is a peculiarity of this cell type. In the pituitary
gland, inhibin activity seems to be specifically directed
to regulate gonadotroph functions, and no other func-
tional role has been identified for this regulatory factor
to date [15,17,19]; thus, the exclusive localization of
inhibins in FSH-producing cells is not surprising. On
the contrary, activins have been reported to modulate
GH and PRL synthesis and secretion [17,18,29], and to
influence the proliferation rate of GH- cells and PRL-
cells [18,19] and these data are in agreement with our
results showing that most GH-cells and a few PRL-
cells express bA subunit which is indicative of the pres-
ence of activin A in these cell-types.
The results of our study on pituitary adenomas
show that the subunits of I/A are more frequently ex-
pressed in nonfunctioning tumors, which are mainly
represented by gonadotroph and null cell adenomas. In
particular, a subunit of inhibin was exclusively ex-
pressed by functionally inactive adenomas, while bA
and bB chains were also detected in functioning tu-
mors, although in a significantly lower number of
cases, in comparison to functioning adenomas. Sugi-
yama et al. [24] analyzing a series of 79 pituitary ade-
nomas, with immunohistochemical (using polyclonal
antibodies directed against porcine subunits of I/A)
and in situ hybridization techniques, reported that a
subunit was found in all types of adenomas, without
any cell type specificity and any differential expression
in functioning and nonfunctioning tumors. On the con-
trary, bA subunit was found to be preferentially ex-
pressed in nonfunctioning gonadotroph adenomas and
in functioning TSH- and ACTH-cell tumors [24]. Pre-
vious investigations on the detection of activin/inhibin
Fig. 4. Immunoreactivity for a-subunit of inhibin in a gonado-
troph adenoma. (Avidin-biotin-peroxidase method, original
magnification 3 400). The inset shows that after absorption
with the related antigen the immunoreactivity is lacking.
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Fig. 5. Immunoreactivity for bA-subunit of inhibin/activin in a a-SU-GO cell adenoma. (Avidin-biotin-peroxidase method, original
magnification 3 400).
Fig. 6. Immunoreactivity for bB-subunit of inhibin/activin in a gonadotroph adenoma. (Avidin-biotin-peroxidase method, original
magnification 3 400).
in pituitary adenomas were performed employing mo-
lecular biology techniques, such as polymerase chain
reaction (PCR) or reverse transcriptase PCR (RT-
PCR), but the results reported were rather conflicting
[22,23,30,31]. The disagreement between our results
and those previously reported may be due to the differ-
ent techniques employed. Molecular biology methods
have a higher sensitivity than immunohistochemistry,
but, on the other hand, they refer only to the presence
of the mRNA and do not provide information about the
actual synthesis and expression of the protein. In addi-
tion, the differences in immunohistochemical results
may depend on the different antibodies employed in
the various studies.
Our study shows that the subunits of I/A are pref-
erentially expressed in gonadotroph adenomas. This
finding, however, seems to be per se unrelated to the
pathogenesis of neoplastic proliferation, since in nor-
mal gonadotrophs we observed the same pattern of
immunoreactivity as in adenomas. However, it has
been recently demonstrated that activin has an an-
tiproliferative effect only in a subset of nonfunctioning
pituitary adenomas, while the majority seems to be
insensitive to this antimitogenic action [32]. D’Abronzo
et al. [33] have hypothesized that the lack of responsiv-
ity to exogenous activin of a subset of human gonadot-
roph adenomas could be due to alterations in the ex-
pression of cell surface activin receptors.
In the present study, we found that GH-cell ade-
nomas, unlike normal GH-cells, were mostly negative
for bA chain of I/A and that, in the few positive cases,
the number of immunoreactive cells was low. These
findings might indicate a role of loss of activin A in the
tumorigenesis of GH-cell adenomas or in uncontrolled
cellular proliferation and hormonal secretion of these
adenomas.
In conclusion, our study has shown that a, bA and
bB subunits of I/A are expressed by specific endocrine
cell type in normal human pituitary. Furthermore, we
have demonstrated that gonadotroph adenomas, as
their normal counterpart, retain the expression of
subunits of I/A, while GH-cells adenomas, unlike nor-
mal somatotroph cells, lack bA subunit expression. Fi-
nally, we reported that nonfunctioning pituitary ade-
nomas characteristically express both inhibins and
activins.
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